Patents by Inventor Keith Canada
Keith Canada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250101093Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: March 14, 2024Publication date: March 27, 2025Applicant: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca Barrett, Keith Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
-
Publication number: 20250027094Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: ApplicationFiled: October 4, 2024Publication date: January 23, 2025Inventors: Scott J. Novick, Nikki Dellas, Vesna Mitchell, Da Duan, Jovana Nazor, Oscar Alvizo, Auric Anthony Sowell-Kantz, Jeffrey C. Moore, Mark A. Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Nicholas M. Marshall, Jay H. Russell, Keith A. Canada
-
Publication number: 20240409648Abstract: The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: August 27, 2024Publication date: December 12, 2024Inventors: Su-Ellen BROWN, Keith CANADA, Lukasz CHLEWICKI, Michael HOWELL, Detlev MENNERICH, Joseph Robert WOSKA, JR.
-
Patent number: 12110493Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: GrantFiled: September 30, 2021Date of Patent: October 8, 2024Assignee: Codexis, Inc.Inventors: Scott J. Novick, Nikki Dellas, Vesna Mitchell, Da Duan, Jovana Nazor, Oscar Alvizo, Auric Anthony Sowell-Kantz, Jeffrey C. Moore, Mark A. Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Nicholas M. Marshall, Jay H. Russell, Keith A. Canada
-
Publication number: 20240124581Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: ApplicationFiled: September 1, 2023Publication date: April 18, 2024Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAAF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, Jr., Haiguang XIAO, Danlin YANG
-
Publication number: 20240060064Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: ApplicationFiled: September 14, 2023Publication date: February 22, 2024Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant S. Murphy, Nicholas Marshall, Jay Russell, Keith A. Canada
-
Patent number: 11795445Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: GrantFiled: May 10, 2021Date of Patent: October 24, 2023Assignee: Codexis, Inc.Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant S. Murphy, Nicholas Marshall, Jay Russell, Keith A. Canada
-
Patent number: 11795219Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: May 11, 2020Date of Patent: October 24, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Walter Carroll Davidson, Pankaj Gupta, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Jr., Haiguang Xiao, Danlin Yang
-
Patent number: 11370818Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: June 25, 2019Date of Patent: June 28, 2022Assignee: Boehringer Ingelheim International GmbHInventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
-
Publication number: 20220153857Abstract: The present invention related to new humanized antanogistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: February 7, 2022Publication date: May 19, 2022Applicant: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias Litzenburger, Sanjaya Singh
-
Patent number: 11242394Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: July 10, 2018Date of Patent: February 8, 2022Assignee: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
-
Publication number: 20220010316Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: ApplicationFiled: September 30, 2021Publication date: January 13, 2022Inventors: Scott J. Novick, Nikki Dellas, Vesna Mitchell, Da Duan, Jovana Nazor, Oscar Alvizo, Auric Anthony Sowell-Kantz, Jeffrey C. Moore, Mark A. Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Nicholas M. Marshall, Jay H. Russell, Keith A. Canada
-
Patent number: 11162105Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: GrantFiled: July 2, 2019Date of Patent: November 2, 2021Assignee: Codexis, Inc.Inventors: Scott J. Novick, Nikki Dellas, Vesna Mitchell, Da Duan, Jovana Nazor, Oscar Alvizo, Auric Anthony Sowell-Kantz, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Nicholas M. Marshall, Jay Russell, Keith A. Canada
-
Publication number: 20210261940Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: ApplicationFiled: May 10, 2021Publication date: August 26, 2021Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant S. Murphy, Nicholas Marshall, Jay Russell, Keith A. Canada
-
Publication number: 20210198355Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: October 9, 2020Publication date: July 1, 2021Applicant: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca Barrett, Keith A. Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
-
Patent number: 11034948Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: GrantFiled: July 2, 2019Date of Patent: June 15, 2021Assignee: Codexis, Inc.Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant Murphy, Nicholas M. Marshall, Jay Russell, Keith A. Canada
-
Patent number: 11028169Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: May 18, 2017Date of Patent: June 8, 2021Assignee: Boehringer Ingelheim International GmbHInventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Haiguang Xiao, Danlin Yang
-
Publication number: 20210095020Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: ApplicationFiled: May 11, 2020Publication date: April 1, 2021Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAFF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, JR., Haiguang XIAO, Danlin YANG
-
Publication number: 20200231684Abstract: The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: December 17, 2019Publication date: July 23, 2020Inventors: Su-Ellen BROWN, Keith CANADA, Lukasz CHLEWICKI, Michael HOWELL, Detlev MENNERICH, Joseph Robert WOSKA, JR.
-
Patent number: 10550189Abstract: The present invention relates to anti-interleukin-36R (anti-IL-36R) binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: April 1, 2015Date of Patent: February 4, 2020Assignee: Boehringer Ingelheim International GmbHInventors: Su-Ellen Brown, Keith Canada, Lukasz Chlewicki, Michael Howell, Detlev Mennerich, Joseph Robert Woska, Jr.
